Co-Marketing Partnership to Expand Reach of Both Companies in the Cannabis and Analytics Space
VANCOUVER, BC, June 30, 2021 /PRNewswire/ – Delic Corp (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform today announced that its subsidiary, DELIC Labs, has entered into a partnership agreement with Agilent, a global leader in life sciences, diagnostics, and applied chemical markets. Under the agreement, Agilent will refer its clients interested in cannabis and hemp analytics and new product development to DELIC Labs and in turn, DELIC Labs will recommend Agilent analytical equipment to its clients looking to purchase new systems. Both companies will participate in sales and marketing initiatives, referrals and instrument training
“Partnering with Agilent, the dominant global analytics experts, is a powerful step for DELIC Labs and brings our cannabis and hemp experience to their broad range of clients, including large pharmaceutical companies,” said DELIC Labs founder and CEO Dr. Markus Roggen. “Our combined expertise will help solve many issues for those exploring the cannabis industry and developing new and unique products to serve an increasingly growing consumer and patient base.”
“Agilent is well-regarded as the premier scientific destination for analytical science and we are honored to collaborate with them through our team at DELIC Labs,” said Matt Stang, Delic CEO and co-founder. “Delic is committed to bringing innovative natural wellness remedies to the general public and this partnership will open up enterprise opportunities for pioneering companies.”
“We continually strive to meet the needs of our customers and there has been a significant interest in cannabis and hemp analytics as well as new product development,” said Greg Kozadjian, Emerging Markets, Business Development, Agilent Technologies. “Partnering with the team at DELIC Labs is a natural fit as they are at the forefront of legal cannabis analytics and research. We are excited to leverage their domain expertise.”
About DELIC Labs (formerly Complex Biotech Discovery Ventures Ltd.)
DELIC Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists, Dr. Markus Roggen and UBC Professor Glenn Sammis, DELIC Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the DELIC Corp family, the leading psychedelic wellness platform, DELIC Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.
About DELIC
DELIC Always Expanding. In All Ways.
DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs (formerly Complex Biotech Discovery Ventures Ltd.), the first licensed entity by Health Canada to conduct research and development of psilocybin vaporization technology, MeetDelic the premiere psychedelic wellness event, and Ketamine Infusion Centers (under binding acquisition agreement), one of the largest ketamine clinics in the country. DELIC is backed by a team of industry and cannabis veterans and a broad network whose mission is to provide education, research, high-quality products, and treatment options to the wellness and psychedelics industries.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Information and Statements
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of DELIC’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but are not limited to, closing of the Transaction, satisfaction of the Escrow Release Conditions, use of proceeds of the Offering, and expectations for other economic, business, and/or competitive factors.
By identifying such information and statements in this manner, DELIC is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of DELIC to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, DELIC has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: the ability of the parties to consummate the Transaction; the ability to satisfy the conditions to closing of the Transaction and the Escrow Release Conditions on the proposed terms and schedule; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the transaction.
Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.
Although DELIC believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and DELIC does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this notice.